PriceTargets.com logo

AVROBIO - AVRO Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 06/20/2024 10:08 PM ET
+0 (0.00%)
Get New AVROBIO Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AVRO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AVRO

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for AVROBIO in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for AVRO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in AVROBIO. This rating has held steady since December 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/17/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/15/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/15/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/14/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/14/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/18/2023MizuhoDowngradeBuy ➝ Neutral$60.00 ➝ $24.00
7/13/2023Wells Fargo & CompanyLower Target$30.00 ➝ $24.00
7/12/2023WedbushDowngradeOutperform ➝ Neutral
3/24/2023Needham & Company LLCReiterated RatingBuy$72.00
12/7/2022BTIG ResearchUpgradeNeutral ➝ Buy$48.00
5/11/2022WedbushLower Target$168.00 ➝ $48.00
5/11/2022BarclaysLower Target$72.00 ➝ $48.00
1/6/2022MizuhoLower TargetBuy ➝ Buy$336.00 ➝ $72.00
1/5/2022Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$84.00 ➝ $36.00
1/5/2022Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$432.00 ➝ $96.00
1/5/2022Needham & Company LLCLower TargetBuy$336.00 ➝ $96.00
1/5/2022BTIG ResearchDowngradeBuy ➝ Neutral
1/5/2022BarclaysBoost TargetOverweight ➝ Overweight$72.00 ➝ $264.00
1/4/2022Stifel EuropeLower Target$108.00 ➝ $48.00
11/19/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$288.00 ➝ $84.00
10/12/2021Morgan StanleyLower TargetOverweight$324.00 ➝ $300.00
8/6/2021BTIG ResearchReiterated RatingBuy$276.00
7/16/2021Morgan StanleyLower TargetOverweight$372.00 ➝ $348.00
6/14/2021BTIG ResearchInitiated CoverageBuy$276.00
5/27/2021Needham & Company LLCInitiated CoverageBuy$336.00
5/14/2021Morgan StanleyLower TargetOverweight$408.00 ➝ $372.00
5/14/2021MizuhoReiterated RatingBuy$336.00
5/4/2021Wells Fargo & CompanyLower TargetOverweight$696.00 ➝ $432.00
5/4/2021MizuhoLower TargetBuy$516.00 ➝ $336.00
5/3/2021Leerink PartnersLower TargetMarket Perform$216.00 ➝ $120.00
3/21/2021Leerink PartnersReiterated RatingHold$216.00
3/9/2021BarclaysInitiated CoverageOverweight$276.00
3/1/2021Stifel NicolausInitiated CoverageHold$168.00
11/18/2020MizuhoBoost TargetPositive ➝ Buy$420.00 ➝ $516.00
11/11/2020Berenberg BankInitiated CoverageBuy$324.00
11/5/2020Leerink PartnersReiterated RatingMarket Perform
10/13/2020Morgan StanleyLower TargetOverweight$420.00 ➝ $408.00
10/6/2020WedbushReiterated RatingOutperform$432.00
9/15/2020MizuhoReiterated RatingBuy$420.00
8/7/2020WedbushReiterated RatingPositive ➝ Outperform$432.00
7/15/2020Morgan StanleyLower TargetOverweight$444.00 ➝ $420.00
(Data available from 7/14/2020 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/16/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/15/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/14/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/16/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/15/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/15/2025
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/14/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/14/2025

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
AVROBIO logo
AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $9.98
Low: $1.40
High: $18.24

52 Week Range

Now: N/A

Volume

206,800 shs

Average Volume

269,831 shs

Market Capitalization

$62.85 million

P/E Ratio

2.03

Dividend Yield

N/A

Beta

1.23

Frequently Asked Questions

What sell-side analysts currently cover shares of AVROBIO?

The following equities research analysts have issued stock ratings on AVROBIO in the last twelve months:
View the latest analyst ratings for AVRO.

What is the current price target for AVROBIO?

0 Wall Street analysts have set twelve-month price targets for AVROBIO in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for AVROBIO in the next year.
View the latest price targets for AVRO.

What is the current consensus analyst rating for AVROBIO?

AVROBIO currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AVRO.

What other companies compete with AVROBIO?

Other companies that are similar to AVROBIO include Inhibikase Therapeutics, Protalix BioTherapeutics, Invizyne Technologies, Achilles Therapeutics and ZIVO Bioscience. Learn More about companies similar to AVROBIO.

How do I contact AVROBIO's investor relations team?

AVROBIO's physical mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The company's listed phone number is (617) 914-8420 and its investor relations email address is [email protected]. The official website for AVROBIO is www.avrobio.com. Learn More about contacing AVROBIO investor relations.